Trial Profile
A single arm, monocentric and exploratory analysis of the first-line treatment of extensive small cell lung cancer with enrotinib combined with EP / EC regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2022
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Erlotinib (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 05 Jul 2022 Results (data cutoff date: 3 Nov 2021) reporting efficacy and safety data published in the Investigational New Drugs
- 31 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology